Viola: [00:36:22] If I was a clinician right now who had type 2 diabetes and had listened to this podcast, I would be a little, a little scared right now listening, thinking, well, all these points that we brought up, you know, collectively and all of this potential grief that could happen to me using this drug, maybe I don't want to use this drug, you know, maybe it's a little bit too risky
Flexible Dosing: With options for both subcutaneous and oral administration, Semaglutide provides flexibility that caters to patient preferences and compliance, a notable advantage over other GLP-1 receptor agonists that are limited to subcutaneous delivery
Gallstone disease and nonalcoholic fatty liver disease in patients with type 2 diabetes: a cross-sectional study
The good news is that the routine itself is simple